Resmed Inc (RMD)

$203.87 -4.58 (-2.20%)
Market Cap 29.57B
Revenue (ttm) 5.15B
Net Income (ttm) 1.40B
EPS (ttm) N/A
PE Ratio 19.35
Forward PE 17.22
Profit Margin 27.22%
Debt to Equity Ratio 0.06
Volume 1,331,100
Avg Vol 1,626,430
Day's Range N/A - N/A
Shares Out 145.06M
Stochastic %K 37%
Beta 0.78
Analysts Sell
Price Target $246.50

Company Profile

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry,...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 858-836-5000
Address:
9001 Spectrum Center Boulevard, San Diego, United States
jjjetplane
jjjetplane Jul. 10 at 7:28 PM
Doubled $MSFT and $NVDA positions today. Started $PODD and $RMD
0 · Reply
IN0V8
IN0V8 Jul. 10 at 3:12 PM
$RMD Jefferies cuts target price to $225 from $240
0 · Reply
Rvvrn9
Rvvrn9 Jul. 7 at 11:56 AM
$IXHL Three choices, $RMD buy before DReAMzz, pay 3× after, or risk losing it to someone like Johnson & Johnson. Get your sh*t together and let’s goooo!!!
2 · Reply
ETAlpha
ETAlpha Jul. 6 at 9:42 PM
Relative Volume Scanner Highlights for 7/6. Capital continues to rotate heavily into Health Technology, driving significant liquidity into the sector. Here are the top-performing structural setups: $YDES - 37.5x $CRNX -2.8x $RMD- 2.0x $LMND - 1.7x $RXRX - 1.6x While price shows the direction, volume measures the conviction behind the move. These massive volume spikes indicate strong institutional footprint-keep them on your watchlist for potential momentum follow-through. "I don’t post noise. Only conviction setups, real positions, real trades. Profile has it all."
0 · Reply
DonCorleone77
DonCorleone77 Jul. 2 at 3:01 AM
$RMD ResMed added to APAC Conviction List at Goldman Sachs Goldman Sachs analysts added ResMed to the firm's APAC Conviction List as part of its monthly update. The firm expects continuous airway pressure therapy patient growth for the company. It keeps a Buy rating on the shares with a A$46.70 price target.
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 30 at 1:00 AM
$RMD Current Stock Price: $198.47 Contracts to trade: $200.0 RMD Jul 17 2026 Call Entry: $2.95 Exit: $5.43 ROI: 84% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 22 at 5:29 PM
$RMD Current Stock Price: $189.04 Contracts to trade: $190.0 RMD Jul 17 2026 Call Entry: $5.40 Exit: $10.49 ROI: 94% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
StrayTrader
StrayTrader Jun. 17 at 8:30 PM
$RMD Morgan Stanley killed it … but it is true that Philips Respironics will likely be back in 2027. Still, this was too much today, and probably worth adding some.
0 · Reply
anachartanalyst
anachartanalyst Jun. 17 at 2:01 PM
$RMD https://anachart.com/wp-content/uploads/2026/06/1781704878_soc-img.jpg
0 · Reply
theonetrue
theonetrue Jun. 17 at 1:15 PM
$FIG $LZB $REXR $RMD $SPCX not helpful
0 · Reply
Latest News on RMD
ResMed price target lowered to $225 from $240 at Jefferies

2026-07-10T13:10:28.000Z - 2 days ago

ResMed price target lowered to $225 from $240 at Jefferies

ResMed price target lowered to $276 from $321 at RBC Capital

2026-07-08T11:45:32.000Z - 4 days ago

ResMed price target lowered to $276 from $321 at RBC Capital

ResMed price target lowered to $225 from $227 at Wells Fargo

2026-07-08T10:25:21.000Z - 4 days ago

ResMed price target lowered to $225 from $227 at Wells Fargo

ResMed to sell software business MatrixCare for $490 million

Jul 7, 2026, 6:07 PM EDT - 4 days ago

ResMed to sell software business MatrixCare for $490 million

Frazier to acquire MatrixCare from ResMed, terms not disclosed

2026-07-07T21:10:11.000Z - 4 days ago

Frazier to acquire MatrixCare from ResMed, terms not disclosed

Frazier Healthcare Partners Announces Definitive Agreement to Acquire MatrixCare

Jul 7, 2026, 5:06 PM EDT - 4 days ago

Frazier Healthcare Partners Announces Definitive Agreement to Acquire MatrixCare

ResMed to sell MatrixCare business to Frazier Healthcare, terms undisclosed

2026-07-07T20:35:31.000Z - 5 days ago

ResMed to sell MatrixCare business to Frazier Healthcare, terms undisclosed

Resmed Announces Agreement to Sell MatrixCare Business

Jul 7, 2026, 4:30 PM EDT - 5 days ago

Resmed Announces Agreement to Sell MatrixCare Business

ResMed Slides: Divestiture of MatrixCare presentation

Jul 7, 2026, 7:00 AM EDT - 5 days ago

ResMed Slides: Divestiture of MatrixCare presentation

ResMed added to APAC Conviction List at Goldman Sachs

2026-07-01T23:15:24.000Z - 10 days ago

ResMed added to APAC Conviction List at Goldman Sachs

Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026

Jun 30, 2026, 4:30 PM EDT - 12 days ago

Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026

ResMed price target lowered to $266 from $290 at KeyBanc

2026-06-22T09:45:57.000Z - 20 days ago

ResMed price target lowered to $266 from $290 at KeyBanc

ResMed downgraded to Equal Weight from Overweight at Morgan Stanley

2026-06-17T09:35:08.000Z - 25 days ago

ResMed downgraded to Equal Weight from Overweight at Morgan Stanley

ResMed price target lowered to $270 from $340 at Citi

2026-06-15T10:21:45.000Z - 27 days ago

ResMed price target lowered to $270 from $340 at Citi

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

Jun 3, 2026, 7:40 AM EDT - 5 weeks ago

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

ResMed Transcript: 46th Annual William Blair Growth Stock Conference

Jun 2, 2026, 5:40 PM EDT - 5 weeks ago

ResMed Transcript: 46th Annual William Blair Growth Stock Conference

ResMed Slides: 46th Annual William Blair Growth Stock Conference

Jun 2, 2026, 5:40 PM EDT - 5 weeks ago

ResMed Slides: 46th Annual William Blair Growth Stock Conference

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

Jun 1, 2026, 4:05 PM EDT - 5 weeks ago

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

May 19, 2026, 4:05 PM EDT - 7 weeks ago

Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

ResMed, Oura partner to expand access to sleep health education

2026-05-19T13:10:59.000Z - 7 weeks ago

ResMed, Oura partner to expand access to sleep health education

Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care

May 19, 2026, 9:00 AM EDT - 7 weeks ago

Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care

ResMed price target lowered to $225 from $254 at Baird

2026-05-01T14:35:07.000Z - 2 months ago

ResMed price target lowered to $225 from $254 at Baird

ResMed price target lowered to $235 from $265 at Stifel

2026-05-01T11:18:33.000Z - 2 months ago

ResMed price target lowered to $235 from $265 at Stifel

ResMed beats quarterly profit estimates, names new CFO

Apr 30, 2026, 6:21 PM EDT - 2 months ago

ResMed beats quarterly profit estimates, names new CFO

ResMed CFO Brett Sandercock to retire, Aaron Bloomer to succeed

2026-04-30T21:15:22.000Z - 2 months ago

ResMed CFO Brett Sandercock to retire, Aaron Bloomer to succeed

ResMed Earnings Call Transcript: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

ResMed Earnings Call Transcript: Q3 2026

ResMed Earnings release: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

ResMed Earnings release: Q3 2026

ResMed Slides: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

ResMed Slides: Q3 2026

ResMed Quarterly report: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

ResMed Quarterly report: Q3 2026

ResMed reports Q3 EPS $2.86, consensus $2.72

2026-04-30T20:20:36.000Z - 2 months ago

ResMed reports Q3 EPS $2.86, consensus $2.72

Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor

Apr 30, 2026, 4:10 PM EDT - 2 months ago

Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026

Apr 30, 2026, 4:05 PM EDT - 2 months ago

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026

Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026

Apr 1, 2026, 4:05 PM EDT - 3 months ago

Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026

Resmed's Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach

Mar 3, 2026, 3:00 AM EST - 4 months ago

Resmed's Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach

ResMed At $250: Missed Opportunity Or A Trap In The Making?

Feb 25, 2026, 12:56 PM EST - 4 months ago

ResMed At $250: Missed Opportunity Or A Trap In The Making?

Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana

Feb 24, 2026, 9:00 AM EST - 4 months ago

Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana

Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge

Feb 3, 2026, 12:29 AM EST - 5 months ago

Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge

NVO

ResMed beats quarterly profit estimates on strong demand for its sleep devices

Jan 29, 2026, 4:41 PM EST - 5 months ago

ResMed beats quarterly profit estimates on strong demand for its sleep devices

ResMed Earnings Call Transcript: Q2 2026

Jan 29, 2026, 4:30 PM EST - 5 months ago

ResMed Earnings Call Transcript: Q2 2026

ResMed Quarterly report: Q2 2026

Jan 29, 2026, 4:30 PM EST - 5 months ago

ResMed Quarterly report: Q2 2026

ResMed Earnings release: Q2 2026

Jan 29, 2026, 4:30 PM EST - 5 months ago

ResMed Earnings release: Q2 2026

ResMed Slides: Q2 2026

Jan 29, 2026, 4:30 PM EST - 5 months ago

ResMed Slides: Q2 2026

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

Jan 29, 2026, 4:05 PM EST - 5 months ago

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

ResMed Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 6 months ago

ResMed Transcript: 44th Annual J.P. Morgan Healthcare Conference

ResMed Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 6 months ago

ResMed Slides: 44th Annual J.P. Morgan Healthcare Conference

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026

Jan 8, 2026, 4:05 PM EST - 6 months ago

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 4:05 PM EST - 7 months ago

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy

Dec 8, 2025, 9:00 AM EST - 7 months ago

Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

Nov 24, 2025, 2:15 PM EST - 8 months ago

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

IDXX

ResMed Transcript: AGM 2025

Nov 19, 2025, 6:00 PM EST - 8 months ago

ResMed Transcript: AGM 2025

ResMed Earnings Call Transcript: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 9 months ago

ResMed Earnings Call Transcript: Q1 2026

ResMed Quarterly report: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 9 months ago

ResMed Quarterly report: Q1 2026

ResMed Earnings release: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 9 months ago

ResMed Earnings release: Q1 2026

ResMed Slides: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 9 months ago

ResMed Slides: Q1 2026

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026

Oct 30, 2025, 4:05 PM EDT - 9 months ago

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025

Oct 9, 2025, 4:05 PM EDT - 9 months ago

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025

ResMed Proxy statement: Proxy Filing

Oct 2, 2025, 8:00 AM EDT - 10 months ago

ResMed Proxy statement: Proxy Filing

ResMed Proxy statement: Proxy Filing

Oct 2, 2025, 8:00 AM EDT - 10 months ago

ResMed Proxy statement: Proxy Filing

ResMed Transcript: Bank of America Global Healthcare Conference 2025

Sep 23, 2025, 8:20 AM EDT - 10 months ago

ResMed Transcript: Bank of America Global Healthcare Conference 2025

ResMed Slides: Corporate Presentation

Sep 18, 2025, 7:00 AM EDT - 10 months ago

ResMed Slides: Corporate Presentation

Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025

Sep 16, 2025, 4:05 PM EDT - 10 months ago

Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025

ResMed Slides: Sustainability Presentation

Sep 12, 2025, 7:00 AM EDT - 10 months ago

ResMed Slides: Sustainability Presentation

The sleep economy is 'having a moment', says medical equipment firm Resmed

Sep 8, 2025, 9:00 PM EDT - 10 months ago

The sleep economy is 'having a moment', says medical equipment firm Resmed

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority

Sep 3, 2025, 4:15 PM EDT - 11 months ago

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds

Aug 27, 2025, 9:00 AM EDT - 11 months ago

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio

Aug 18, 2025, 4:15 PM EDT - 11 months ago

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio

Resmed beats quarterly profit estimates on strong demand for sleep devices

Jul 31, 2025, 4:53 PM EDT - 1 year ago

Resmed beats quarterly profit estimates on strong demand for sleep devices

ResMed Earnings Call Transcript: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings Call Transcript: Q4 2025

ResMed Annual report: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Annual report: Q4 2025

ResMed Earnings release: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings release: Q4 2025

ResMed Slides: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Slides: Q4 2025

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

Jul 31, 2025, 4:05 PM EDT - 1 year ago

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

Spot Outliers Like ResMed Early with Money Flows

Jul 30, 2025, 6:08 AM EDT - 1 year ago

Spot Outliers Like ResMed Early with Money Flows

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

Jul 1, 2025, 4:05 PM EDT - 1 year ago

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

May 15, 2025, 9:00 AM EDT - 1 year ago

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

Resmed Acquires VirtuOx

May 1, 2025, 9:00 AM EDT - 1 year ago

Resmed Acquires VirtuOx

ResMed slightly beats quarterly profit estimates on sleep devices demand

Apr 23, 2025, 5:08 PM EDT - 1 year ago

ResMed slightly beats quarterly profit estimates on sleep devices demand

ResMed Earnings Call Transcript: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings Call Transcript: Q3 2025

ResMed Quarterly report: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Quarterly report: Q3 2025

ResMed Earnings release: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings release: Q3 2025

ResMed Slides: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Slides: Q3 2025

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

Resmed Names Salli Schwartz as Chief Investor Relations Officer

Apr 21, 2025, 5:00 PM EDT - 1 year ago

Resmed Names Salli Schwartz as Chief Investor Relations Officer

Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

Apr 3, 2025, 9:00 AM EDT - 1 year ago

Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

Mar 19, 2025, 8:00 AM EDT - 1 year ago

New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

Mar 11, 2025, 9:00 AM EDT - 1 year ago

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

Feb 26, 2025, 3:00 AM EST - 1 year ago

ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

Jan De Witte joins GHO Capital as Operating Partner

Feb 11, 2025, 4:30 AM EST - 1 year ago

Jan De Witte joins GHO Capital as Operating Partner

IART

ResMed beats quarterly profit estimates on demand for sleep disorder devices

Jan 30, 2025, 5:21 PM EST - 1 year ago

ResMed beats quarterly profit estimates on demand for sleep disorder devices

ResMed Earnings Call Transcript: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Earnings Call Transcript: Q2 2025

ResMed Earnings release: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Earnings release: Q2 2025

ResMed Quarterly report: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Quarterly report: Q2 2025

ResMed Slides: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Slides: Q2 2025

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025

Jan 30, 2025, 4:05 PM EST - 1 year ago

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025

ResMed Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 6:00 PM EST - 1 year ago

ResMed Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

ResMed Slides: FY 2025

Jan 13, 2025, 6:00 PM EST - 1 year ago

ResMed Slides: FY 2025

ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025

Jan 9, 2025, 4:05 PM EST - 1 year ago

ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025

ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:05 PM EST - 1 year ago

ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound

Dec 23, 2024, 2:59 PM EST - 1 year ago

Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound

INSP LLY

Canada Sleep Apnea Devices Market Research Report 2024: Opportunities and Forecasts to 2029 Featuring Braebon Medical, VitalAire, FPM Solutions, SomnoMed, and ResMed

Dec 4, 2024, 4:13 AM EST - 1 year ago

Canada Sleep Apnea Devices Market Research Report 2024: Opportunities and Forecasts to 2029 Featuring Braebon Medical, VitalAire, FPM Solutions, SomnoMed, and ResMed

jjjetplane
jjjetplane Jul. 10 at 7:28 PM
Doubled $MSFT and $NVDA positions today. Started $PODD and $RMD
0 · Reply
IN0V8
IN0V8 Jul. 10 at 3:12 PM
$RMD Jefferies cuts target price to $225 from $240
0 · Reply
Rvvrn9
Rvvrn9 Jul. 7 at 11:56 AM
$IXHL Three choices, $RMD buy before DReAMzz, pay 3× after, or risk losing it to someone like Johnson & Johnson. Get your sh*t together and let’s goooo!!!
2 · Reply
ETAlpha
ETAlpha Jul. 6 at 9:42 PM
Relative Volume Scanner Highlights for 7/6. Capital continues to rotate heavily into Health Technology, driving significant liquidity into the sector. Here are the top-performing structural setups: $YDES - 37.5x $CRNX -2.8x $RMD- 2.0x $LMND - 1.7x $RXRX - 1.6x While price shows the direction, volume measures the conviction behind the move. These massive volume spikes indicate strong institutional footprint-keep them on your watchlist for potential momentum follow-through. "I don’t post noise. Only conviction setups, real positions, real trades. Profile has it all."
0 · Reply
DonCorleone77
DonCorleone77 Jul. 2 at 3:01 AM
$RMD ResMed added to APAC Conviction List at Goldman Sachs Goldman Sachs analysts added ResMed to the firm's APAC Conviction List as part of its monthly update. The firm expects continuous airway pressure therapy patient growth for the company. It keeps a Buy rating on the shares with a A$46.70 price target.
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 30 at 1:00 AM
$RMD Current Stock Price: $198.47 Contracts to trade: $200.0 RMD Jul 17 2026 Call Entry: $2.95 Exit: $5.43 ROI: 84% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 22 at 5:29 PM
$RMD Current Stock Price: $189.04 Contracts to trade: $190.0 RMD Jul 17 2026 Call Entry: $5.40 Exit: $10.49 ROI: 94% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
StrayTrader
StrayTrader Jun. 17 at 8:30 PM
$RMD Morgan Stanley killed it … but it is true that Philips Respironics will likely be back in 2027. Still, this was too much today, and probably worth adding some.
0 · Reply
anachartanalyst
anachartanalyst Jun. 17 at 2:01 PM
$RMD https://anachart.com/wp-content/uploads/2026/06/1781704878_soc-img.jpg
0 · Reply
theonetrue
theonetrue Jun. 17 at 1:15 PM
$FIG $LZB $REXR $RMD $SPCX not helpful
0 · Reply
theflynews
theflynews Jun. 17 at 1:14 PM
Pre-Market Fly By for Wednesday, June 17th: Breaking Stock Market News $SPCX $LZB $RMD $REXR $FIG
0 · Reply
ripster47
ripster47 Jun. 17 at 11:22 AM
$RMD | Morgan Stanley Downgrades ResMed to Equalweight with $230 PT on Margin Pressures and Competitive Re-entry Morgan Stanley stays cautious as component cost headwinds and Philips’ re-entry into the US device market temper upside. 🔹 Follow @tenet_research for more analyst insights on other tickers.
0 · Reply
theflynews
theflynews Jun. 17 at 9:46 AM
ResMed just downgraded at Morgan Stanley, here's why - $RMD - https://thefly.com/RMD
0 · Reply
StrayTrader
StrayTrader Jun. 8 at 2:02 PM
$RMD whether reality or not, the retatrutide news from Lilly is going to put a lid on ResMed with the narrative that obesity and sleep apnea will be greatly reduced
0 · Reply
RollTheDice369
RollTheDice369 Jun. 8 at 8:46 AM
$LLY Bye bye $RMD
0 · Reply
StrayTrader
StrayTrader Jun. 5 at 2:33 PM
$RMD hopefully clears 200 today and stays there. On the numbers, it should not in any case be less than 200. And no, neither GLP-1’s nor some pill with cannabinoids and breathing stabilizers is going to make any difference.
0 · Reply
KopOut
KopOut Jun. 5 at 2:10 PM
$RMD started position at 198.43
0 · Reply
StrayTrader
StrayTrader Jun. 5 at 2:54 AM
$RMD belongs back over $200 … maybe soon
0 · Reply
ConsistentSpike
ConsistentSpike Jun. 4 at 2:20 PM
$RMD https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-and-oura-link-consumer-sleep-data-to-clinical-care-pa
0 · Reply
InLongtoRetire
InLongtoRetire Jun. 4 at 2:06 AM
$RMD RemSleep is waiting for you.
0 · Reply
ConsistentSpike
ConsistentSpike Jun. 3 at 2:08 PM
$RMD https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/is-it-time-to-reassess-resmed-rmd-after-this-years-25-share
0 · Reply
RogueFF7
RogueFF7 Jun. 2 at 1:16 PM
$IXHL $RMD CPAP works, but one glove doesn’t fit all. If adherence weren’t a major issue, even companies like ResMed wouldn’t be actively exploring pharmacologic and alternative treatment pathways in sleep apnea. Critics tend to frame this as if the debate is purely “CPAP works vs CPAP doesn’t work.” That misses the real issue: CPAP efficacy is strong in controlled use, but real-world adherence remains a persistent limitation across a large portion of OSA patients. And this isn’t just theory. Sleep medicine experts with affiliations to ResMed have participated in advisory roles for emerging OSA programs, including Incannex’s IHL-42X initiative. Dr. Alison Wimms was cited in that context as representing ResMed in an advisory capacity at the time of that engagement. So it’s not “CPAP is threatened” It’s that the market itself acknowledges a gap between clinical efficacy and real-world treatment coverage.
1 · Reply